Rocket Pharmaceuticals, Inc. (RCKT)
- Previous Close
22.10 - Open
22.16 - Bid 21.95 x 100
- Ask 22.01 x 200
- Day's Range
21.69 - 22.30 - 52 Week Range
14.89 - 32.53 - Volume
858,483 - Avg. Volume
728,017 - Market Cap (intraday)
1.989B - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
-- - EPS (TTM)
-2.92 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.33
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
www.rocketpharma.comRecent News: RCKT
Performance Overview: RCKT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RCKT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RCKT
Valuation Measures
Market Cap
1.99B
Enterprise Value
1.64B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.94
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.03%
Return on Equity (ttm)
-50.01%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-245.6M
Diluted EPS (ttm)
-2.92
Balance Sheet and Cash Flow
Total Cash (mrq)
373.18M
Total Debt/Equity (mrq)
5.08%
Levered Free Cash Flow (ttm)
-121.64M